Abridged profile of Emmanuel O. OKORO 

 

PRESENT POSITION & AFFILIATION:      Professor of Medicine

University of Ilorin 

PMB 1515, Ilorin Nigeria.

+2348037301311

This email address is being protected from spambots. You need JavaScript enabled to view it.,

@unilorin.edu.ng

CONCURRENT APPOINTMENT:  Honorary Consultant Physician, University of Ilorin Teaching Hospital, Nigeria.

PREVIOUS POSITIONS:

  • Head, Department of Medicine, University of Ilorin Teaching Hospital, Ilorin.
  • Head, Department of Medicine, University of Ilorin, Nigeria.
  • Visiting Professor of Medicine & Adjunct Professor of Pharmacology, Niger Delta University Wilberforce Island, Nigeria.
  • Consultant/Chief of Internal Medicine. King Fahd Specialist Hospital, Buraidah, Al Qassim, Saudi Arabia .
  • Visiting Associate Professor in Pharmacology, University of Maiduguri, Nigeria
  • Honorary Lecturer in Pharmacology, Bayero University, Kano .
  • Clinical Instructor, School of Medicine, University of Sydney, Australia.
  • Lecturer (Part-time) in Pharmacology, B.Sc. Nursing Programme, University of Technology, Sydney,  Australia.
  • Fellow in Hypertension, Experimental & Clinical Pharmacology Research of Department of Pharmacology University of Sydney at the Department of Clinical Pharmacology, Royal North Shore Hospital, Sydney, Australia .

CORE AREAS OF COMPETENCE

  • Hypertension and Type 2 diabetes, their Pharmacology/Pharmacovigilance

AREA OF RESEARCH INTERESTS

  1. As above
  2. Delivery of quality /affordability of basic health care services in resource constraint environment.

QUALIFICATIONS

  1. MB; B.Ch (1980).
  2. FWACP (Fellowship of West African College Of Physicians -1988).
  3. Masters in Pharmacology (by Research)1992

ACADEMIC PUBLICATIONS:  

  1. Okoro, Emmanuel Obi (2016), Effective Treatment Matters: Revitalizing Pharmacovigilance in PHARMACOVIGILANCE  (editors: IR Edwards, M. Lindquist), Springer International Publishing , Switzerland © 2017, DOI.101.1007/978-3-319-404000-4-12.( BOOK)
  1. Okoro, Emmanuel .O, Etebu, Ebitimitula N., Oyejola, Benjamin A,  Blood pressure and body preference  in traditional communities in Ilorin metropolis, Nigeria  Cardiovascular Endocrinology 2015, 4(2), 53-59 , Wolters Kluwer Health, Inc, USA  /UK.
  2. Okoro E.O, Oyejola BA Aspirin and Diabetes Care in Nigeria: Treatment or Exploitation? Journal of Clinical Research  & Bioethic  2015, 6(2)1-7, see http://doi.org/10.4172/2155-9627.1000227 
  1. Okoro E.O, Oyejola BA, Etebu EN, Sholagberu H, Kolo PM, Chijioke A, Adebisi SA, Body size preference  among Yoruba in three Nigerian communities , Eating  and Weight Disorders 2014, 19: 77-88, Springer international Publishing Switzerland .
  2. Okoro, Emmanuel Obi, “TOWARDS BETTER PREVENTION /CONTROL OF HYPERTENSION AND DIABETES” 143rd Inaugural lecture, 27 February 2014, University of Ilorin, Nigeria  see www.unilorin.edu.ng
  1. Kolo PM, Ajiboye PO, Yusuf AD, Omotoso ABO,  Okoro E.O , Psychotropic medications and QTc  parameters  in Nigerians, British Journal of Medicine and Medical Research 2012,  2(3), 434-443.
  2. Okoro E.O, Oyejola BA, Chijioke, Long term effects of  dietary sucrose on diabetic control in black Africans African  Journal of Endocrinology and Metabolism 2011, 10( 1), 13-16.
  3. Okoro E.O, Sholagberu HO, Kolo PM, MOBILE PHONE OWNERSHIP AMONG NIGERIANS WITH DIABETES: Journal of African Health Sciences 2010,  10(2), 182- 185.
  1. Okoro E.O, Kolo PM, Davies, AE, Low-cost is the key to quality outcome in type 2 diabetes in Nigeria IN HANDBOOK OF TYPE 2 DIABETES IN THE MIDDLE AGED AND ELDERLY”, Editor: Alberto T. Lignalli ,  Copyright ©2009 by  Nova Science Publishers, ISBN:978-1-60692-617-8, 400 Oser Avenue, Suite 1600 Hauppauge, NY 11788, USA( BOOK).
  2. Okoro E.O. Oyejola BA, Body image preference among Nigerians with type 2 diabetes, Practical Diabetes International 2008, 25 (6) ,228-231,  John Willey & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex, PO198SQ, UK.
  3. Okoro E.O, Kuranga SA, Olatinwo AWO, Kolo PM, Ayetoro SO, “Beware that positive widal test could be a killer” Pharamacovigilance 2008, 7(1), 24 – 25
  1. Mokuolu O.A., Okoro E.O., Ayetoro S.O, and Adewara A.A, Effect of Artemisinin-Based Treatment Policy on Consumption Pattern of Antimalarials. American Journal of Tropical Medicine and Hygiene 2007, 76(1), 7 – 11.The Sheridan Press, 450 Fame Avenue, Hanover, Pennsylvania 17331, USA.
  2. Okoro E.O, Funsho SO, Oyedokun OA, Oyejola BA, Effect of dietary sucrose intake on glycaemic control in Nigerians with type 2 diabetes International Journal of Clinical Practice 2007, 61(6), 916 – 919. Blackwell Publishing Ltd. Garsington Road, Oxford, lOX42DQ, UK.
  3. Okoro E.O, Yusuf M, Salawu HO, Oyejola BA, Outcome of Diabetic Hyperglycaemic Emergencies in Nigeria Cohort: Journal of Chinese Clinical Medicine 2007, 2(2), 1-7.
  4. Okoro E.O, Oyejola BA Long term effects of hydrochlorothiazide on diabetic control and blood pressure in Nigerians. Kuwait Medical Journal 2005, 37(1) 18-21. Official Journal of Kuwait Medical Association. P.O.Box 1202 130-13 safat, State of Kuwait.
  5. Okoro E.O, Adewara AA, Davies AE, Quality of Diabetic Care in Nigeria: a patient satisfaction survey. Diabetes International, 2005, 13(1), 21-23. Publication of International Diabetes Federation. FSG Communications, Cambridge CB5OJD, U.K.
  6. Okoro E.O, Oyejola BA Inadequate control of blood pressure in Nigerians with diabetes. Ethnicity & Disease 2004, 14(1), 83-87. The Official Journal of the International Society of Hypertension in Blacks. Allen Press Inc., Lawrence, Kansas 66044, USA.
  7. Okoro E.O Treating hypertension in individuals of African descent with type 2 diabetes (invited contributor). Ethnicity & Disease 2004, 14(1),201-203. The Official Journal of the International Society of Hypertension in Blacks. Allen Press Inc., Lawrence, Kansas 66044, USA.
  8. Okoro E.O, Adejumo AO, Oyejola BO, Quality of Diabetic care in Nigeria: report of a self Journal of Diabetes and its Complications 2002, 16(2), 159 - 164. An Official Journal of American Diabetes Association Elsevier Sciences Ltd, 650 Avenue of the Americas, New York, NY 10011, USA.
  9. Okoro E.O, Oyejola BA, Jolayemi ET, Pattern of salt taste perception and blood pressure in normotensive offspring of hypertensive and diabetic patients. Annals of Saudi Medicine 2002, 22 (3/4), 249-251. NAJD Press, Riyadh, Saudi Arabia. Official Publication of King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyad 11211, Saudi Arabia
  10. Okoro E.O, Jolayemi ET, Oyejola BA Observations on the use of low dose hydrochlorothiazide in the treatment hypertension in Diabetic Nigerians, Heart Drug/excellence in cardiovascular trials 2001, 1, 83-88.Kargers Medical and Scientific Publishers, CH-4009 Basel, Switzerland.
  11. Okoro Emmanuel .O, Davies Arthur E, Sponsorship of Educational Programmes in Nigerian Medical and Pharmacy School by Pharmaceutical companies: possible risk implications for public health. Ethics & Medicine 2001, 17 (1), 52-60. The Bioethics Press, P.O.Box 1032, Highland Park, Illinois, 60035 USA & the Paternoster Press, P.O.Box 300, Kingston Broadway, Carlisle, Cumbria CA30QS, England.
  12. Okoro E.O, Davies AE Quality of Medicinal Drug advertisements in Medical Journals: a comparative study. Journal of Health & Social Issues 2000, 3 (1), 33-37. Published by Department of Sociology, University of Ado Ekiti, Nigeria in conjunction with Swedish Agency for Research in Collaboration with Developing Countries/Sweden International Agency (SAREC/SIDA)
  13. Hamidu LJ, Okoro, E.O, Ali MA Blood Pressure Profile in Nigerian Children East African Medical Journal 2000, 77 (4), 180-184. Official Publication of Kenya Medical Association (Since 1923), P.O. Box 41632, Nairobi, Kenya.
  14. Okoro E.O Overlap in the Pharmacology of L-type Ca2+ channel Blockers and 5HT2 receptor Antagonists in Rat Aorta. Journal of Pharmacy and Pharmacology 1999, 51, 953957.Published by Royal Pharmaceutical Society of Great Britain. 1, Lambeth High Street, London SE17JN, England (UK). 
  15. Okoro E.O, Marwood JF, Bichi LA Effects of sodium nitroprusside and ketanserin on K+- induced contractions of guinea pig aorta. Nigerian Journal of Pure & Applied Sciences 1999. 14,1-6, Published by Department of Biochemistry, Faculty of Science, University of Ilorin, Nigeria.
  16. Okoro E.O, Uroghide GE & Jolayemi ET Salt taste sensitivity and blood pressure in a group of adolescent school children in Southern Nigeria. East African Medical Journal 1998, 75(4), 196-200, Official Publication of Kenya Medical Association, P.O. Box 41632, Nairobi, Kenya.
  17. Okoro E.O, Marwood JF Effects of 5HT2 receptor antagonists on responses to potassium depolarization in isolated rat aorta.  Clinical and Experimental Pharmacology and Physiology 1997, 25(1), 34 -39 Official Publication of Australian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and High Blood Pressure Council of Australia (HBPRCA) Blackwell Sciences Pty Ltd, P.O. Box 378, Carlton, Victoria 3053, Australia.
  18. Okoro E.O, Marwood JF, Stokes GS The interaction between Ca2+, verapamil and ketanserin in rat tail arteries and aortae. Journal of Cardiovascular Pharmacology 1995, 25, 603-610. Raven Press, New York, USA.
  19. Jolayemi ET, Okoro E.O On the estimation of mean IC50. BioScience Research Communication 1995, 7(2), 175-178, Published by Bioscience Study Group, Department of Biochemistry, University of Ilorin, Nigeria
  20. Stokes GS, Johnson HJ, Okoro E.O, Boutagy J, Managhan JC, Marwood JF Comparative and combined efficacy and safety of doxazosin and enalapril in hypertensive patients. Clinical and Experimental Hypertension 1994, 16, 709-727, Marcel Dekker Inc, 270 Madison Avenue, New York, NY 10016, USA.
  21. Stokes GS, Brooks P, Johnson H, Monaghan JC, Okoro E.O, Kelly D The effects of sulindac and diclofenac in essential hypertension controlled by treatment with a beta blocker and or diuretic.  Clinical and Experimental Hypertension 1990, A13,1169-1179, Marcel Dekker Inc, 270 Madison Avenue,  New York, NY 10016, USA.
  22. Olowoyeye, J, Okoro E.O, Omotosho ABO Oral labetolol in the urgent treatment of severe hypertension. Tropical and Geographical Medicine 1986, 38(1), 73-78, Foris Publications, P.O. Box 509, 3300AM, Dordrecht, Netherlands.
  23. Other Publications: See world wide web or search Google

 

RECENT COMMUNITY SERVICE 

  1. Editorial Adviser, Sahel Medical Journal (Home –Usman DanFodio University Teaching Hospital, Sokoto, Nigeria).
  2. Member, Editorial board, DRUG SAFETY-case reports (Home –New Zealand).
  3. Member, National Drug Advisory Safety Committee (NDSAC) & Consultant to NAFDAC (In this capacity and with others the under listed were  accomplished  ) : 
  4. Cohort Event Monitoring (CEM) study which  rapidly  characterized the side effects / safety  profile of  a new type of malaria medicines( ACTs )  in  the Nigerian population with  funding from  NAFDAC, WHO  & OTHER  DEVELOPMENT PARTNERS.
  5. Pharmacovigilance training for health care  providers nationwide  at  all tiers of  health   services  with focus on malaria therapy  which aimed to ensure  effective/safe use of medicines and expand treatment coverage with funding from  NAFDAC & PUBLIC HEALTH PROGRAMMES AND DEVELOPMENT PARTNERS.
  6. Establishment of a Regional /Zonal Pharmacovigilance centre in University of Ilorin Teaching hospital in conjunction with NAFDAC which covers  the six states in North Central  geo-political  region with an estimated population of over 20 million) .
  7. Draft National Pharmacovigilance policy for Nigeria now approved at the highest level of government since 2014
  8. Initiated  an exchange programme between American Medical Students Association (AMSA) and the then Faculty of Health Sciences, University of Ilorin    with  Professor O. Ogunbode (  then Dean ) and  Professor Gabriel Smilkstein of University of Kentucky, Louiseville, USA; Dorothy Culjat, Project Director, American Medical Students’ Association/Foundation, Reston, Virginia, USA; Mr. Bettina Acossta, Registrar, School of Medicine, University of Washington, Seattle, USA  & Dr. Roger Gerstle, MD, now of University of Michigan, USA . 
  9. Advocacy programme for Health Policy makers (Commissioners of Health, Permanent Secretaries, Medical Directors etc.) in the North East geopolitical zone which included Borno, Yobe, Bauchi, Gombe, Taraba and Adamawa States preparatory to the introduction of  Drug Revolving Scheme  as part of health systems  under the auspices of the defunct  Petroleum Trust Fund (PTF)
  10. Pioneer Nodal Officer (Head) of SERVICOM responsible for setting quality standards and ensuring adherence to set benchmarks of health care services delivered at  University of Ilorin Teaching Hospital, Nigeria.
  11. Pioneer Chairman, Committee for Safety and Efficacy of Medicines and Medical Devices, University of Ilorin Teaching Hospital, Nigeria. January 2005.  

PATENTS/GRANTS  

  1. Patents (Patent #RP 12790 of 1997) of a software programme for estimating drug potency and efficacy based on the intellectual work (research findings) copywritted  from publication # 30 i.e. Jolayemi ET & Okoro EO (1995). 
  2. Grant Awardee & Project Manager: United Kingdom DFID/Federal Public Service Reform Programme, Service Improvement Challenge Fund, at the University of Ilorin Teaching Hospital. With this grant, it was possible to show high quality basic health care services could be delivered at a price that ordinary people could pay for that met their expectations and be also financially rewarding to the provider institution with resources available as at 2009 (See details in academic publication # 5 above).

 

MEMBERSHIP OF LEARNED /PROFESSIONAL SOCIETIES

Member, Nigeria Medical Association (NMA)

Fellow, Endocrine and Metabolic Society of Nigeria (EMSON) International Society of Pharmacovigilance (ISOP)

 

Dated this day: 01 December 2016